Zhao B, et al. - Researchers tested erlotinib + bevacizumab as a treatment strategy in non-small cell lung cancer (NSCLC). They analyzed data from relevant randomized controlled trials (RCTs), with a focus on overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and adverse effects. They used random-effects models to estimate pooled hazard ratio and relative risk. The meta-analysis including 10 studies with a total of 2802 participants revealed that erlotinib plus bevacizumab enhanced OS for epidermal growth factor receptor (EGFR)-mutant patients. The reported adverse effects included rash and diarrhea. These adverse effects were common but acceptable. Overall, the recommendation of the combination treatment as the preferable option for EGFR-mutant patients is valid.